Subjective effectiveness of ibogaine treatment for problematic opioid consumption: Short-and long-term outcomes and current psychological functioning

Opioid addiction is described as a major contributor to global disease burden and a pressing public health crisis in the United States and Europe, with high rates of chronic use, dependence and overdose deaths. Mainline treatments such as opioid maintenance therapies (OMT) are effective for some patients but require long-term use, monitoring and carry risks of relapse and iatrogenic harms; this has motivated interest in single‑session pharmacological approaches that might acutely interrupt withdrawal and craving while producing psychotherapeutic effects (for example, insight or increased motivation) to support longer-term change. Davis and colleagues situate ibogaine — a naturally occurring alkaloid historically used in West Central Africa and noted for oneirophrenic, psychedelic and dissociative subjective effects — as a candidate single‑dose intervention for opioid detoxification. Prior small clinical and observational reports suggested rapid mitigation of withdrawal and reductions in craving, but long‑term evidence and larger samples have been limited. The present observational study therefore set out to evaluate short‑ and long‑term self‑reported opioid use outcomes and current psychological functioning among a larger sample of people who received ibogaine treatment at a single clinic in Mexico between 2012 and 2015.

Participants were recruited using a contact list supplied by the medical director of Crossroads Treatment Center, an ibogaine‑assisted residential detoxification programme in Mexico. Of 336 people treated at Crossroads between 2012 and 2015, 285 had active contact details and were invited by e‑mail to complete an anonymous web survey between August and December 2015. Inclusion criteria were receipt of ibogaine at Crossroads in 2012–2015, age 18 or over, English fluency and ability to complete the online questionnaire. Of 285 contacted, 134 began the survey; after incomplete responses and exclusion of 13 people who sought treatment for non‑opioid problems, the analytic sample comprised 88 participants. Crossroads provided a one‑week residential ibogaine‑assisted detoxification. Applicants underwent onsite medical screening including history and physical, 12‑lead ECG, drug testing and basic bloodwork. Clinic exclusions included severe psychiatric disorders (psychosis, bipolar I, severe eating disorders, impaired reality testing), major medical problems (cardiac disease, prolonged QTc, severe respiratory or gastrointestinal disease, epilepsy, severe brain injury, abnormal electrolytes or hepatic/renal impairment), current pregnancy, and recent use of alcohol, stimulants, psychiatric medications or long‑acting opioids. Ibogaine hydrochloride (Voacanga‑derived, GMP‑certified) was administered at doses around 15 mg/kg (±5 mg/kg depending on weight and polysubstance use). Patients received continuous cardiac monitoring, intravenous fluids and electrolytes and 24/7 medical supervision; a short residential stay with psychological support and aftercare planning followed dosing. Measures combined investigator‑developed items and standard instruments. The survey asked about primary opioid type (heroin or prescription opioids), years of use, days used in the month before treatment, post‑treatment changes in use (increased, decreased, unchanged, abstinent) and opioid use in the 6 months prior to survey. The authors developed items assessing subjective treatment effectiveness, post‑treatment craving, acute subjective effects of ibogaine (rated −2 to +2), and two single items rating spiritual and personal meaningfulness of the experience on 1–7 scales. Treatment history (prior OMT and psychosocial treatments) and demographics were collected. Current psychological functioning was measured with the DASS‑21 (depression, anxiety, stress subscales) and the Satisfaction With Life Scale (SWLS). For analysis, frequencies described the total sample (n = 88). The sample was split into treatment responders (those reporting sustained abstinence or decreased use after treatment) versus non‑responders (no change or increased use). Group comparisons used chi‑square or Fisher’s exact tests with two‑proportion z‑tests, and t‑tests for continuous measures. Analyses were conducted in SPSS v23. The extracted text notes an inability, due to an anonymous survey error, to identify with certainty which participants also received 5‑MeO‑DMT introduced midway through the clinic’s procedures; exploratory analyses using treatment date were performed to probe this change.

Sample characteristics indicated 73% male, 50% aged 18–34 and 89% identifying as White/Caucasian. About 59% had received ibogaine at least 1 year before the survey. Primary problems were split between heroin (51%) and prescription opioids (49%). Most participants (72%) had used their primary opioid for 4 or more years and 21% for 10 or more years; 69% reported using their primary opioid on 30 of 30 days in the month prior to treatment. On subjective effectiveness, 61% rated ibogaine as "Very effective" and 85% would choose the same treatment again; 71% judged ibogaine as "Much better" than other treatments they had tried. Regarding acute treatment effects, 80% reported that withdrawal symptoms were eliminated or drastically reduced during treatment. Half the sample (50%) reported reduced craving for at least 1 week post‑treatment, and 25% reported reduced craving lasting 3 months or more. In terms of substance use outcomes, 30% reported never returning to opioid use after ibogaine; among these abstainers, 54% had remained abstinent for at least 1 year and 31% for 2 or more years. At the time of survey, 41% of all participants reported being abstinent from opioids for at least 6 months. Although 70% of participants experienced a relapse at some point after treatment, 48% reported that their opioid consumption decreased relative to pretreatment levels; 17% reported no change and 6% reported increased use. Comparing responders (abstinence or decreased use) versus non‑responders (no change or increased use), there were no broad demographic or treatment‑history differences except that responders were more likely to report prescription opioids as their primary substance (56% vs 25%), χ2(1,87)=5.90, p = .021, φ = 0.24. Acute subjective effects commonly endorsed were visions/visuals (88%), elimination or drastic reduction of withdrawal (80%), physical discomfort (74%), geometric shapes (68%) and gaining insightful knowledge about the self (67%). Between outcome groups, most acute‑effect reports did not differ, but responders reported greater agreement that their ibogaine experience provided insight into the causes of their addiction (means: responders 0.41, SD 1.1; non‑responders −0.47, SD 1.1), t(79)=−3.0, p = .004, d = 0.80. Responders also scored higher on spiritual meaningfulness (responders mean 4.4, SD 1.7; non‑responders 3.2, SD 2.2), t(86)=−2.6, p = .011, d = 0.61, while personal meaningfulness did not differ. On current psychological functioning, treatment responders had lower depression scores on the DASS‑21 (responders mean 10.6, SD 8.8; non‑responders 17.6, SD 9.6), t(74)=2.7, p = .008, d = 0.76, and lower anxiety scores (responders 6.2, SD 6.5; non‑responders 10.8, SD 7.1), t(74)=2.4, p = .018, d = 0.68. Stress scores did not differ significantly, t(74)=1.8, p = .071, though the effect size was moderate (d = 0.53). Responders reported greater subjective well‑being on the SWLS (responders mean 3.9, SD 1.7; non‑responders 2.7, SD 1.4), t(86)=−2.8, p = .006, d = 0.77. The authors attempted an exploratory comparison by treatment date to assess the potential impact of the clinic’s mid‑period addition of 5‑MeO‑DMT but report no statistically significant differences between likely recipients and non‑recipients in primary outcomes based on those dates.

Davis and colleagues interpret their findings as broadly consistent with earlier observational and small clinical studies: a large proportion of participants reported rapid relief of opioid withdrawal during the ibogaine session and short‑term reductions in craving, and meaningful percentages achieved sustained abstinence or reductions in use. The study observed slightly higher abstinence rates (30%) than some prior web‑survey work, and many abstainers maintained long durations of abstinence (over half for ≥1 year, about one third for ≥2 years). The investigators also note that almost half of participants who relapsed nonetheless reported decreased opioid consumption relative to pretreatment. The authors highlight an association between positive treatment outcomes and the subjective content of the ibogaine experience, specifically reports of spiritual meaningfulness and insight into the causes of addiction. They suggest that reductions in withdrawal and craving may be most likely to translate into sustained benefit when accompanied by strong spiritual or insightful experiences, drawing a parallel with research on mystical experiences mediating outcomes in classic hallucinogen trials. From this perspective, the team proposes that preparatory and integrative interventions might augment the therapeutic impact of an ibogaine session, although they acknowledge that these hypotheses require testing in controlled designs. Several limitations are acknowledged that restrict generalisability and causal inference. Recruitment was limited to a single facility in Mexico and relied on an available contact list; the anonymous, retrospective web survey design is subject to self‑selection, recall bias and social desirability effects, and non‑responders or those unreachable may have had different outcomes. The extraction notes that clinical procedures changed midway through the treatment window to include 5‑MeO‑DMT after ibogaine, and due to a survey error the authors could not definitively identify which participants received this adjunct; although exploratory date‑based analyses showed no significant differences, the combined‑drug effect cannot be fully ruled out. The observational design and self‑report outcome measures mean the study cannot establish efficacy or safety relative to controls. Given these caveats, the authors conclude that ibogaine appears promising as an alternative approach for opioid detoxification and reduction of problematic use, but emphasise the need for rigorous randomised controlled trials and safety evaluations before changes in legal or clinical status can be justified. They recommend future research to test whether enhancing preparatory and integrative processes that foster insight and spiritual meaning improves long‑term outcomes.